secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000950170-25-101624
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q2 product revenue $150M (+72% YoY); AUVELITY sales $119.6M
------------------------------------------------------------------

- Total net product revenue $150.0M, up 72% YoY and 24% sequentially.
- AUVELITY net sales $119.6M (+84% YoY); ~192k prescriptions written in Q2.
- Net loss narrowed to $48.0M ($0.97/share) from $79.3M ($1.67/share) in Q2 2024.
- Cash $303.0M; management says sufficient to fund operations into cash flow positivity.
- Pipeline: sNDA for AXS-05 in Alzheimer's agitation on track for Q3 2025; NDA for AXS-12 in narcolepsy expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/0000950170-25-101624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer